Recruiting

NCT Number: NCT07334457

Study of Platelet Population Changes Under Circulatory Support With ECMO

Advances in flow cytometry techniques have led to a better understanding of platelet phenotypes and have revealed the existence of four major platelet populations with distinct functional properties (native, proaggregating, procoagulating, or apoptotic). These phenotypes have a significant impact on the hemostatic capacity of blood platelets, and a proportional change in these populations during ECMO treatment could, at least in part, contribute to the observed complications.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Cardiac Failure Cardiovascular Diseases Heart Diseases Heart Failure Respiration Disorders Respiratory Failure Respiratory Insufficiency Respiratory Tract Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Service d'anesthésie-réanimation - CHU de Strasbourg - France

Strasbourg, 67091, France

Location status: Recruiting

Location contact

Béatrice HECHLER, Statistician

SUB_INVESTIGATOR

Charles TACQUARD, MD, PhD

CONTACT

[email protected]

33.3.69.55.16.08

Charles TACQUARD, MD, PhD

PRINCIPAL_INVESTIGATOR

Laurent SATTLER, MD

SUB_INVESTIGATOR

Marie MULLER, MD

SUB_INVESTIGATOR

Thomas RESCHWEIN, MD

SUB_INVESTIGATOR

Walid OULEHRI, MD

SUB_INVESTIGATOR

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adult patient (≥18 years) treated in one of the intensive care units of the Anesthesia and Intensive Care Department at Strasbourg University Hospital.
Implanted with veno-arterial or veno-venous ECMO within the previous 24 hours.

Exclusion criteria

Subject who has expressed their opposition to participating in the study.
Subject under legal protection.
Subject under guardianship or curatorship.

Treatment and study plan

Primary outcomes

Proportional Changes in the Different Platelet Populations (native, proaggregating, procoagulant, or apoptotic)

Time frame: Days 1, 3, and 7 after the initiation of ECMO treatment.

Proportional Changes in the Different Platelet Populations (native, proaggregating, procoagulant, or apoptotic) on Days 1, 3, and 7 after the initiation of ECMO treatment.

Study contacts

Contact information is provided by the study sponsor or research team.

Charles TACQUARD, MD, PhD

CONTACT

[email protected]

33.3.69.55.16.08

Sponsors and collaborators

Lead sponsor

University Hospital, Strasbourg, France

Other

Registry information

Acronym: ECMO-POP

Important dates

Study start: 2025
Primary completion: 2027
Study completion: 2027
First posted: Jan 12, 2026
Registry last updated: Jan 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting